Phase 2, randomised, placebo-controlled trial of pemvidutide, a GLP-1/glucagon dual receptor agonist, in subjects with overweight or obesity: a 24-week interim analysis

被引：0
|
作者：
Aronne, L. [1 ]
Harris, M. S. [2 ]
Roberts, M. S. [2 ]
Suschak, J. [2 ]
Tomah, S. [2 ]
He, L. [2 ]
Yang, J. [2 ]
Frias, J. P. [3 ]
Browne, S. K. [2 ]
机构：
[1] Weill Cornell Med, New York, NY USA
[2] Altimmune Inc, Gaithersburg, MD USA
[3] Veloc Clin Res, Los Angeles, CA USA
来源：
DIABETOLOGIA | 2023年 / 66卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
60
引用
收藏
页码：S33 / S34
页数：2
相关论文
共 50 条
  • [1] Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, in Subjects with Overweight or Obesity-A 48-Week, Placebo-Controlled, Phase 2 (MOMENTUM) Trial
    Aronne, Louis
    Harris, M. Scott
    Roberts, M. S.
    Suschak, John J.
    Tomah, Shaheen
    Kasper, Jonathan
    He, Liang
    Yang, Jay
    Frias, Juan P.
    Browne, Sarah K.
    DIABETES, 2024, 73
  • [2] Survodutide, a glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist, improves cardiometabolic parameters in adults with obesity: analysis of a placebo-controlled, randomised phase 2 trial
    Le Roux, C.
    Steen, O.
    Lucas, K. J.
    Ekinci, E., I
    Startseva, E.
    Unseld, A.
    Hennige, A. M.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [3] Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
    Roux, Carel W. le
    Steen, Oren
    Lucas, Kathryn J.
    Startseva, Elena
    Unseld, Anna
    Hennige, Anita M.
    LANCET DIABETES & ENDOCRINOLOGY, 2024, 12 (03): : 162 - 173
  • [4] Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo- controlled study
    Harrison, Stephen A.
    Browne, Sarah K.
    Suschak, John J.
    Tomah, Shaheen
    Gutierrez, Julio A.
    Yang, Jay
    Roberts, M. Scot
    Harris, M. Scott
    JOURNAL OF HEPATOLOGY, 2025, 82 (01)
  • [5] Pemvidutide, a glp-1/glucagon dual receptor agonist, significantly reduces liver fat, fibro-inflammation, and bodyweight in patients with non-alcoholic fatty liver disease: a 24-week multicenter, randomized, double-blind, placebo-controlled trial
    Harrison, Stephen
    Tomah, Shaheen
    Suschak, John
    Roberts, Scot
    Yang, Jay
    He, Liang
    Georges, Bertrand
    Rodwell-Green, Lakisha
    Brown, Randy
    Harris, M. Scott
    Browne, Sarah
    JOURNAL OF HEPATOLOGY, 2023, 78 : S54 - S55
  • [6] Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial
    Lennart Tonneijck
    Mark M. Smits
    Marcel H. A. Muskiet
    Trynke Hoekstra
    Mark H. H. Kramer
    A. H. Jan Danser
    Michaela Diamant
    Jaap A. Joles
    Daniël H. van Raalte
    Diabetologia, 2016, 59 : 1412 - 1421
  • [7] Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial
    Tonneijck, Lennart
    Smits, Mark M.
    Muskiet, Marcel H. A.
    Hoekstra, Trynke
    Kramer, Mark H. H.
    Danser, A. H. Jan
    Diamant, Michaela
    Joles, Jaap A.
    van Raalte, Daniel H.
    DIABETOLOGIA, 2016, 59 (07) : 1412 - 1421
  • [8] Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial
    Ji, Linong
    Gao, Leili
    Jiang, Hongwei
    Yang, Jing
    Yu, Lei
    Wen, Jie
    Cai, Chenghang
    Deng, Huan
    Feng, Liqi
    Song, Baili
    Ma, Qingyang
    Qian, Lei
    ECLINICALMEDICINE, 2022, 54
  • [9] IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study
    Ji, Linong
    Jiang, Hongwei
    An, Pei
    Deng, Huan
    Liu, Meng
    Li, Li
    Feng, Liqi
    Song, Baili
    Han-Zhang, Han
    Ma, Qingyang
    Qian, Lei
    ECLINICALMEDICINE, 2021, 39
  • [10] Glucagon and GLP-1 receptor dual agonist survodutide improved liver histology in people with MASH and fibrosis: Results from a randomized, double-blind, placebo-controlled phase 2 trial
    Sanyal, Arun J.
    Bedossa, Pierre
    Fraessdorf, Mandy
    Neff, Guy
    Lawitz, Eric
    Bugianesi, Elisabetta
    Anstee, Quentin M.
    Hussain, Samina Ajaz
    Newsome, Philip N.
    Ratziu, Vlad
    Hosseini-Tabatabaei, Azadeh
    Schattenberg, Joern M.
    Noureddin, Mazen
    Alkhouri, Naim
    Younes, Ramy
    JOURNAL OF HEPATOLOGY, 2024, 80 : S4 - S5
12345